Lantern Pharma Inc.
LTRN
$4.44
-$0.13-2.85%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 6.18M | 6.12M | 6.09M | 5.77M | 5.62M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 20.50M | 21.26M | 22.22M | 21.20M | 19.54M |
Operating Income | -20.50M | -21.26M | -22.22M | -21.20M | -19.54M |
Income Before Tax | -19.25M | -19.88M | -20.78M | -19.09M | -17.75M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -19.25 | -19.88 | -20.78 | -19.09 | -17.75 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -19.25M | -19.88M | -20.78M | -19.09M | -17.75M |
EBIT | -20.50M | -21.26M | -22.22M | -21.20M | -19.54M |
EBITDA | -20.48M | -21.24M | -22.20M | -21.18M | -19.53M |
EPS Basic | -1.78 | -1.84 | -1.93 | -1.78 | -1.65 |
Normalized Basic EPS | -1.11 | -1.15 | -1.19 | -1.11 | -1.03 |
EPS Diluted | -1.78 | -1.84 | -1.93 | -1.78 | -1.65 |
Normalized Diluted EPS | -1.11 | -1.15 | -1.19 | -1.11 | -1.03 |
Average Basic Shares Outstanding | 43.21M | 43.19M | 43.15M | 43.00M | 43.09M |
Average Diluted Shares Outstanding | 43.21M | 43.19M | 43.15M | 43.00M | 43.09M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |